| Goldfine AB
Assessing the cardiovascular safety of diabetes therapies. [Journal Article]
N Engl J Med 2008 Sep 11; 359(11):1092-5.
Full Citation | Publisher Full Text | Find Related Articles |
| Joffe HV, Parks MH, Meyer RJ, et al.
Rosiglitazone and the FDA. [JOURNAL ARTICLE]
N Engl J Med 2007 Aug 29.
Full Citation | Publisher Full Text | Find Related Articles |
| Rosen CJ
The rosiglitazone story--lessons from an FDA Advisory Committee meeting. [Journal Article]
N Engl J Med 2007 Aug 30; 357(9):844-6.
Full Citation |
| Psaty BM, Furberg CD
Rosiglitazone and cardiovascular risk. [Comment, Editorial]
N Engl J Med 2007 Jun 14; 356(24):2522-4.
Full Citation | Publisher Full Text | Find Related Articles |
| Psaty BM, Furberg CD
The record on rosiglitazone and the risk of myocardial infarction. [Comment, Editorial]
N Engl J Med 2007 Jul 5; 357(1):67-9.
Full Citation | Publisher Full Text | Find Related Articles |
| Califf RM, Kramer JM
The balance of benefit and safety of rosiglitazone: important lessons for our system of drug development and postmarketing assessment. [JOURNAL ARTICLE]
Pharmacoepidemiol Drug Saf 2008 Jul 24; 17(8):782-786.
Full Citation | Find Related Articles |
| Krall RL
Rosiglitazone and the FDA. [Comment, Letter]
N Engl J Med 2007 Oct 25; 357(17):1776-7; author reply 1777.
Full Citation | Find Related Articles |
| Nissen SE, Wolski K, Topol EJ
Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus. [Journal Article]
JAMA 2005 Nov 23; 294(20):2581-6.
Abstract | Full Citation | Publisher Full Text | Find Related Articles |
| Hiatt WR
Observational studies of drug safety--aprotinin and the absence of transparency. [Comment, Journal Article]
N Engl J Med 2006 Nov 23; 355(21):2171-3.
Full Citation | Publisher Full Text | Find Related Articles |
  |
